RESOURCES
Welcome to our website with an overview of our scientific papers and posters
Here we present a curated selection of our research contributions. Our team’s work covers a wide range of topics, from fundamental discoveries to methodological advances. Explore our collection to get an insight into our ongoing scientific work.
A selection of our posters
PD3D models are jacks-of-all-trades for cancer research and therapy response prediction
Turning data into information – Using PD3D models to guide colorectal cancer therapy by Optim.AI
Collaboration partner:
Kyan Therapeutics
Tackling the complexity of cancer therapy by combining Optim.AI and PD3D models
Collaboration partner:
Kyan Therapeutics
Mix and match – A comprehensive pipeline for matched patient-derived PDX and PD3D models for cancer research and preclinical drug development
Collaboration partner:
Charles River
Let’s get physiological! Impact of media conditions on drug response to targeted therapies in CRC organoids
Collaboration partners:
NMI TT Pharmaservices
ASC Oncology
Personalized identification of cancer treatments in real-time: TumOC – a tumor organoid-on-a-chip platform for online cell vitality measurements
Collaboration partner:
Fraunhofer Institut for Cell Therapy and Immunology
Co-culture of patient-derived tumor organoids with autologous immune cells for therapy response prediction
Biomarker panel predicts response to MEK inhibition in colorectal cancer
Personalized medicine for sarcoma patients – HERE, NOW
The Bad, the Ugly and the Ultra-rare – all cancers are equal in the face of personalized medicine
Collaboration partners:
Helios Klinikum Berlin-Buch
ASC Oncology
Meeting Medical Need – Development of a High-Thoughput Assay Using Pancreatic Cancer Patient Derived Organoids as a Tool for Personalized Medicine
Collaboration partner:
PRECODE
PD3D models – new age in cancer research and clinical diagnostics
Collaboration partner:
ASC Oncology
Patient-derived 3D sarcoma model – robust system for sarcoma research and personalized therapy selection
Collaboration partners:
Helios Klinikum Berlin-Buch
ASC Oncology
A selection of our publications
Functional Precision Medicine Successfully Guides Therapeutic Regimen of ‘Cancer of Unknown Primary’ Later Classified as Triple-Negative Breast Cancer: A Case Report
Ruhe L, Heibl S, Czompo M, Haybaeck J, Loskutov J, Regenbrecht MJ, Thaler J, Wedeken L, Regenbrecht CRA. Functional precision medicine successfully guides therapeutic regimen of ‘cancer of unknown primary’ later classified as triple-negative breast cancer: a case report. Case Rep Oncol. Case Rep Oncol (2024) 17 (1): 490–496. doi: 10.1159/000538137
Photon and Proton irradiation in Patient-derived, Three-Dimensional Soft Tissue Sarcoma Models
Roohani S, Loskutov J, Heufelder J, Ehret F, Wedeken L, Regenbrecht M, Sauer R, Zips D, Denker A, Joussen_x000D_AM, Regenbrecht CRA, Kaul D: Photon and Proton irradiation in Patient-derived, Three-Dimensional_x000D_Soft Tissue Sarcoma Models. BMC Cancer. 2023, 23(1):577.
A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer
Kendzia S, Franke S, Kröhler T, Golob-Schwarzl N, Schweiger C, Toeglhofer AM, Skofler C, Uranitsch S,_x000D_El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Yaspo M, Reinhard_x000D_C, Schäfer R, Keilholz U, Regenbrecht C, Schicho R, Fickert P, Lax SF, Erdmann F, Schulz MH, Kiemer_x000D_AK, Haybaeck J, Kessler SM: A combined computational and functional approach identifies IGF2BP2_x000D_as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer. Mol Cancer._x000D_2023 May 30;22(1):89.
A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer
Pfohl U, Loskutov J, Bashir S, Kühn R, Herter P, Templin M, Mamlouk S, Belanov S, Linnebacher M, Bürtin_x000D_F, Vetter M, Reinhard C, Wedeken L, Regenbrecht CRA. A RAS-Independent Biomarker Panel to Reliably_x000D_Predict Response to MEK Inhibition in Colorectal Cancer. Cancers (Basel). 2022 Jul 1;14(13):3252. doi:_x000D_10.3390/cancers14133252. PMID: 35805024; PMCID: PMC9265111.
RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence
Regan JL, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, Jourdan T, Haybaeck J, Mumberg D,_x000D_Henderson D, Győrffy B, Regenbrecht CRA, Keilholz U, Schäfer R, Lange M. RNA sequencing of long-term_x000D_label-retaining colon cancer stem cells identifies novel regulators of quiescence. iScience. 2021 May_x000D_24;24(6):102618. doi: 10.1016/j.isci.2021.102618. PMID: 34142064; PMCID: PMC8185225.
Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer
Sankarasubramanian S, Pfohl U, Regenbrecht CRA, Reinhard C, Wedeken L. Context Matters-Why We_x000D_Need to Change From a One Size Fits all Approach to Made- to-Measure Therapies for Individual_x000D_Patients With Pancreatic Cancer. Front Cell Dev Biol. 2021 Nov 4;9:760705. doi: 10.3389/fcell.2021.760705._x000D_PMID: 34805167; PMCID: PMC8599957.
Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed
Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelmann Q, Reinhard C, Regenbrecht CRA, Wedeken_x000D_L. Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed. Cells._x000D_2021 Apr 17;10(4):928. doi: 10.3390/cells10040928. PMID: 33920536; PMCID: PMC8072767.
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models
Dahlmann M, Gambara G, Brzezicha B, Popp O, Pachmayr E, Wedeken L, Pflaume A, Mokritzkij M, Gül-_x000D_Klein S, Brandl A, Schweiger-Eisbacher C, Mertins P, Hoffmann J, Keilholz U, Walther W, Regenbrecht C,_x000D_Rau B, Stein U. Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular_x000D_signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models. Mol Cancer._x000D_2021 Oct 21;20(1):129. doi: 10.1186/s12943-021-01430-7. PMID: 34670579; PMCID: PMC8529724.
Heterogeneous pathway activation and drug response modelled in colorectal-tumorderived 3D cultures
Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G,_x000D_Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA: Heterogeneous pathway activation_x000D_and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet. 2019 Mar_x000D_29;15(3):e1008076. doi: 10.1371/journal.pgen.1008076. Erratum in: PLoS Genet. 2019 May 29;15(5):e1008183._x000D_PMID: 30925167; PMCID: PMC6457557.
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
Moritz Schütte, Thomas Risch, Nilofar Abdavi-Azar, Karsten Boehnke, Dirk Schumacher, Marlen Keil, Reha_x000D_Yildiriman, Christine Jandrasits, Tatiana Borodina, Vyacheslav Amstislavskiy, Catherine L. Worth, Caroline_x000D_Schweiger, Sandra Liebs, Martin Lange, Hans- Jörg Warnatz, Lee M. Butcher, James E. Barrett, Marc_x000D_Sultan, Christoph Wierling, Nicole Golob-Schwarzl, Sigurd Lax, Stefan Uranitsch, Michael Becker, Yvonne_x000D_Welte, Joseph Lewis Regan, Maxine Silvestrov, Inge Kehler, Alberto Fusi, Thomas Kessler, Ralf Herwig, Ulf_x000D_Landegren, Dirk Wienke, Mats Nilsson, Juan A. Velasco, Pilar Garin-Chesa, Christoph Reinhard, Stephan_x000D_Beck, Reinhold Schäfer, Christian R. A. Regenbrecht, David Henderson, Bodo Lange, Johannes Haybaeck,_x000D_Ulrich Keilholz, Jens Hoffmann, Hans Lehrach, Marie-Laure Yaspo: Molecular dissection of colorectal_x000D_cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature_x000D_Communications 02/2017; 8:14262., DOI:10.1038/ncomms14262
Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures
Karsten Boehnke, Philip W Iversen, Dirk Schumacher, María José Lallena, Rubén Haro, Joaquín Amat, Johannes_x000D_Haybaeck, Sandra Liebs, Martin Lange, R. Schafer, Christian R A Regenbrecht, Christoph Reinhard,_x000D_Juan A Velasco: Assay Establishment and Validation of a High-Throughput Screening Platform for_x000D_Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. Journal of Biomolecular Screening_x000D_05/2016; 21(9)., DOI:10.1177/1087057116650965
